Endocrine Abstracts

Introduction: Pathogenesis of pituitary adenomas is largely unknown thus, identification of genes specific for various types of pituitary tumors should enable better understanding of their biology.The aim of our study was to analyze differences in gene expression between functional (FA) and non-functional (NFA) pituitary adenomas. For this goal, we considered folate receptor (FOLR1) shown by previous study (Evans et al. 2003) to be overexpr...

The routine use of adjuvant RAI treatment in low-risk DTC remains controversial due to the lack of unequivocal evidences of its effectiveness in radically operated subjects. The aim of the study was a retrospective evaluation of long-term outcomes of combined DTC treatment to evaluate the impact of adjuvant RAI therapy in the low risk group. Primary hypothesis was: ‘if adjuvant RAI treatment was unnecessary, a delay in RAI administration would have no impact on long-term ...

Introduction: Reliable prognostic factors are crucial to choose the optimal treatment strategy and follow-up for differentiated thyroid carcinomas (DTC) patients. Thus, the aim of the study was a retrospective evaluation of prognostic factors of cancer relapse in patients treated in a single institution.Material: The study group consisted of 510 DTC patients, staged pT1b-T4N0-N1M0, treated with total thyroidectomy followed by complementary 131...

Objectives: Recent studies on BRAFV600E mutation, known as initiating event in papillary thyroid carcinoma (PTC) and related to more aggressive clinical course of the disease, revealed its significant influence on gene expression profile suggesting that BRAF(+)PTCs represent a molecular subtype of PTC. However, the human material disables distinction of possible molecular causes of cancer from its effects, unlike the mouse model. The main goal of our project was to find genes ...

Introduction: BRAFV600E mutation is the most frequent alteration in papillary thyroid carcinoma (PTC). Although its relation to factors of poor prognosis was demonstrated in many studies the use of BRAF as a predictive marker in clinical treatment of PTC patients is controversial. The aim of our study was to analyze molecular consequences of BRAFV600E mutation in a transgenic mouse model performed for this purpose and to refer the obtained results to...

Introduction: Follicular adenomas (FTA) and carcinomas (FTC) are thyroid tumours that are indistinguishable in the fine needle aspiration biopsy (FNAB). In our previous research we concentrated on post-operative material and developed the classifier, which discriminates the FTC and FTA, based on formalin-fixed paraffin-embedded (FFPE) material. The classifier was based on expression of five genes and gave the promising sensitivity of 71% and specificity of 72%. The aim of the ...

Introduction: Discovery of V600E (BRAFT1799A) mutation in papillary thyroid carcinoma (PTC) widened our knowledge about mechanisms of its molecular initiation. It has been revealed that activating mutations of the BRAF kinase are much more frequent in PTC than RET rearrangements.Aim of the study: Estimation of V600E BRAF mutation frequency in PTC and analysis of differences in gene expression profile between papillary thyroid car...